New Insights into the Pathophysiology of Gynecological Cancers 2.0
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: closed (31 March 2023) | Viewed by 5427
Special Issue Editor
2. Department of Pathology, University of Valencia, 46010 Valencia, Spain
Interests: endometrial cancer; endometriosis; animal models; immunotherapy; RANK; angiogenesis; fertility; pain
Special Issue Information
Dear Colleagues,
Endometrial and ovarian tumours are the most preponderant and deadliest gynaecological cancers. Classical chemo and radio therapeutic approaches are hampered by toxicity and show limited efficacy especially at advanced disease stages. In this scenario, the identification of key targets and development of new therapies are in demand. This Special Issue is open to studies aimed at the (1) identification/description of new relevant pathways in the onset and progression of the disease and (2) assessment of the potential therapeutic effects of alternative approaches by functional experimentation in disease models:
- Identification/description of new pathways/targets is expected to include in vitro experiments for the identification of novel targets for the treatment and/or characterization of novel pathways involved in the onset and/or progression of any ovarian/endometrial cancer subtype. For example, better knowledge of the pathways transduced by oncogenes (K-ras, P53, etc.) might identify alternative targets for subsequent intervention and thus overcome classical limitations in targeting oncogenes. Since IJMS is a journal of molecular science, pure clinical studies are not suitable unless combined with biomolecular analysis. In this regard, exploratory studies identifying overexpressed/downregulated potential targets in clinical samples might be covered by this Issue as long as a) expression is described at the mRNA and protein level simultaneously and b) analysis extends over different types/subtypes of either endometrial or ovarian cancer so as to identify master regulators of disease progression.
- The evaluation of therapeutic potential of alternative approaches is expected to include “functional experimentation” in “preclinical models” of endometrial and ovarian cancer. “Preclinical” refers to studies in homologous or heterologous animal models of disease and also in in vitro models with special interest in those using organoids as the subject of experimentation,. The term “functional experimentation” includes any kind of pharmacological or biological intervention, where the effects of alternative (other than chemotherapy) therapies are assayed. Interventions of interest in the models covered by the topic are exemplified by (but not limited to) immunotherapy, vaccines, nanoparticles, or CAR-T therapies.
Dr. Raúl Gómez
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- endometrial cancer
- ovarian cancer
- immunotherapy
- new targets
- animal models
- humanized mouse models
- organoids
- nanoparticles
- CAR-T
- oncogenes
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
